R A Heller1, T F Raven2, T Swing1, K Kunzmann3, V Daniel4, P Haubruck1, M Akbar5, P A Grützner6, G Schmidmaier1, B Biglari6, A Moghaddam2. 1. Heidelberg Trauma Research Group, Trauma and Reconstructive Surgery, Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, Heidelberg University Hospital, Heidelberg, Germany. 2. Aschaffenburg Trauma and Orthopaedic Research Group, Center for Trauma Surgery, Orthopedics and Sports Medicine Aschaffenburg-Alzenau, Aschaffenburg, Germany. 3. Institute for Medical Biometry and Informatics, Heidelberg University Hospital, Heidelberg, Germany. 4. Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany. 5. Spine Center, Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, Heidelberg University Hospital, Heidelberg, Germany. 6. Department of Paraplegiology, Berufsgenossenschaftliche Unfallklinik Ludwigshafen, Ludwigshafen, Germany.
Abstract
STUDY DESIGN: Prospective observational study. OBJECTIVES: To describe the correlation between CCL-2, CCL-3, CCL-4 and CXCL-5 serum levels and remission after traumatic spinal cord injury (SCI) in a human protocol compared with animal studies. SETTING: Germany, Rhineland-Palatinate (Rheinland-Pfalz). METHODS: We examined the serum levels of CCL-2, CCL-3, CCL-4 and CXCL-5 over a 12-week period; in particular, at admission and 4, 9 and 12 h, 1 and 3 days and 1, 2, 4, 8 and 12 weeks after trauma. According to our study design, we matched 10 patients with TSCI and neurological remission with 10 patients with an initial ASIA A grade and no neurological remission. In all, 10 patients with vertebral fracture without neurological deficits served as control. Our analysis was performed using a Luminex Cytokine Panel. Multivariate logistic regression models were used to examine the predictive value with respect to neurological remission vs no neurological remission. RESULTS: The results of our study showed differences in the serum expression patterns of CCL-2 in association with the neurological remission (CCL-2 at admission P=0.013). Serum levels of CCL-2 and CCL-4 were significantly different in patients with and without neurological remission. The favored predictive model resulted in an area under the curve (AUC) of 93.1% in the receiver operating characteristic (ROC) analysis. CONCLUSIONS: Our results indicate that peripheral serum analysis is a suitable concept for predicting the patient's potential for neurological remission after TSCI. Furthermore, the initial CCL-2 concentration provides an additional predictive value compared with the NLI (neurological level of injury). Therefore, the present study introduces a promising approach for future monitoring concepts and tracking techniques for current therapies. The results indicate that future investigations with an enlarged sample size are needed in order to develop monitoring, prognostic and scoring systems.
STUDY DESIGN: Prospective observational study. OBJECTIVES: To describe the correlation between CCL-2, CCL-3, CCL-4 and CXCL-5 serum levels and remission after traumatic spinal cord injury (SCI) in a human protocol compared with animal studies. SETTING: Germany, Rhineland-Palatinate (Rheinland-Pfalz). METHODS: We examined the serum levels of CCL-2, CCL-3, CCL-4 and CXCL-5 over a 12-week period; in particular, at admission and 4, 9 and 12 h, 1 and 3 days and 1, 2, 4, 8 and 12 weeks after trauma. According to our study design, we matched 10 patients with TSCI and neurological remission with 10 patients with an initial ASIA A grade and no neurological remission. In all, 10 patients with vertebral fracture without neurological deficits served as control. Our analysis was performed using a Luminex Cytokine Panel. Multivariate logistic regression models were used to examine the predictive value with respect to neurological remission vs no neurological remission. RESULTS: The results of our study showed differences in the serum expression patterns of CCL-2 in association with the neurological remission (CCL-2 at admission P=0.013). Serum levels of CCL-2 and CCL-4 were significantly different in patients with and without neurological remission. The favored predictive model resulted in an area under the curve (AUC) of 93.1% in the receiver operating characteristic (ROC) analysis. CONCLUSIONS: Our results indicate that peripheral serum analysis is a suitable concept for predicting the patient's potential for neurological remission after TSCI. Furthermore, the initial CCL-2 concentration provides an additional predictive value compared with the NLI (neurological level of injury). Therefore, the present study introduces a promising approach for future monitoring concepts and tracking techniques for current therapies. The results indicate that future investigations with an enlarged sample size are needed in order to develop monitoring, prognostic and scoring systems.
Authors: Matthew Bank; Adam Stein; Cristina Sison; Annemarie Glazer; Navdeep Jassal; Dayna McCarthy; Matthew Shatzer; Barry Hahn; Radhika Chugh; Peter Davies; Ona Bloom Journal: Arch Phys Med Rehabil Date: 2014-11-15 Impact factor: 3.966
Authors: Brian K Kwon; Elena B Okon; Ward Plunet; Darryl Baptiste; Karim Fouad; Jessica Hillyer; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff Journal: J Neurotrauma Date: 2010-06-16 Impact factor: 5.269
Authors: B Biglari; A Büchler; T Swing; E Biehl; H J Roth; T Bruckner; G Schmidmaier; T Ferbert; H J Gerner; A Moghaddam Journal: Spinal Cord Date: 2012-11-27 Impact factor: 2.772
Authors: Arash Moghaddam; Christopher Child; Thomas Bruckner; Hans Jürgen Gerner; Volker Daniel; Bahram Biglari Journal: Int J Mol Sci Date: 2015-04-09 Impact factor: 5.923
Authors: Sandra J Campbell; V Hugh Perry; Fernando J Pitossi; Angus G Butchart; Mariela Chertoff; Sara Waters; Robert Dempster; Daniel C Anthony Journal: Am J Pathol Date: 2005-05 Impact factor: 4.307
Authors: Arash Moghaddam; André Sperl; Raban Heller; Kevin Kunzmann; Viola Graeser; Michael Akbar; Hans Jürgen Gerner; Bahram Biglari Journal: PLoS One Date: 2016-07-22 Impact factor: 3.240
Authors: Bahram Biglari; Raban Arved Heller; Manuel Hörner; Andre Sperl; Tobias Bock; Bruno Reible; Patrick Haubruck; Paul Alfred Grützner; Arash Moghaddam Journal: J Spinal Cord Med Date: 2019-06-18 Impact factor: 1.985
Authors: Michael C Tanner; Raban Heller; Fabian Westhauser; Matthias Miska; Thomas Ferbert; Christian Fischer; Simone Gantz; Gerhard Schmidmaier; Patrick Haubruck Journal: Trials Date: 2018-05-30 Impact factor: 2.279
Authors: Patrick Haubruck; Raban Heller; Michael C Tanner; Volker Daniel; Gerhard Schmidmaier; Farhoud Bolourchi; Arash Moghaddam; Christian Fischer Journal: Diagnostics (Basel) Date: 2018-08-24